New Recommendations from the 1999 American College of Cardiology/American Heart Association Acute Myocardial Infarction Guidelines

Abstract

Spanish

French

OBJECTIVE:

To review literature relating to significant changes in drug therapy recommendations in the 1999 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for treating patients with acute myocardial infarction (AMI).

DATA SOURCES:

1999 ACC/AHA AMI guidelines, English-language clinical trials, reviews, and editorials researching the role of drug therapy and primary angioplasty for AMI that were referenced in the guidelines were included. Additional data published in 2000 or unpublished were also included if relevant to interpretation of the guidelines.

STUDY SELECTION:

The articles selected influence AMI treatment recommendations.

DATA SYNTHESIS:

Many clinicians and health systems use the ACC/AHA AMI guidelines to develop treatment plans for AMI patients. This review highlights important changes in AMI drug therapy recommendations by reviewing the results of recent clinical trials. Insights into evolving drug therapy strategies that may impact future guideline development are also described.

CONCLUSIONS:

Several changes in drug therapy recommendations were included in the 1999 AMI ACC/AHA guidelines. There is emphasis on administering fibrin-specific thrombolytics secondary to enhanced efficacy. Selection between fibrin-specific agents is unclear at this time. Low response rates to thrombolytics have been noted in the elderly, women, patients with heart failure, and those showing left bundle-branch block on the electrocardiogram. These patient groups should be targeted for improved utilization programs. The use of glycoprotein (GP) IIb/IIIa receptor inhibitors in non-ST—segment elevation MI was emphasized. Small trials combining reduced doses of thrombolytics with GP IIb/IIIa receptor inhibitors have shown promise by increasing reperfusion rates without increasing bleeding risk, but firm conclusions cannot be made until the results of larger trials are known. Primary percutaneous coronary intervention (PCI) trials suggest lower mortality rates for primary PCI when compared with thrombolysis alone. However, primary PCI, including coronary angioplasty, is only available at approximately 13% of US hospitals, making thrombolysis the preferred strategy for most patients. Clopidogrel has supplanted ticlopidine as the recommended antiplatelet agent for patients with aspirin allergy or intolerance following reports of a better safety profile. The recommended dose of unfractionated heparin is lower than previously recommended, necessitating a separate nomogram for patients with acute coronary syndromes. Routine use of warfarin, either alone or in combination with aspirin, is not supported by clinical trials; however, warfarin remains a choice for antithrombotic therapy in patients intolerant to aspirin. β -Adrenergic receptor blockers continue to be recommended, and emphasis is placed on improving rates of early administration (during hospitalization), even in patients with moderate left ventricular dysfunction. New recommendations for drug treatment of post-AMI patients with low high-density lipoprotein cholesterol and/or elevated triglycerides are included, with either niacin or gemfibrozil recommended as an option. Supplementary antioxidants are not recommended for either primary or secondary prevention of AMI, with new data demonstrating lack of efficacy for vitamin E in primary prevention. Estrogen replacement therapy or hormonal replacement therapy should not be initiated solely for prevention of cardiovascular disease, but can be continued in cardiovascular patients already taking long-term therapy for other reasons. Bupropion has been added as a new treatment option for smoking cessation. As drug therapy continues to evolve in treating AMI, more frequent updates of therapy guidelines will be necessary.

Keywords

acute myocardial infarction acute non-ST—segment elevation American College of Cardiology American Heart Association

Get full access to this article

View all access options for this article.

References

ACC/AHA guidelines for the management of patients with acute myocardial infarction 1999. Updated guideline [cited 2000 Jul 23]. Available from: URL: http://www.americanheart.org/Scientific/statements/1999/AMI/edits/jac1716pre.htm.

ACC/AHA guidelines for the management of patients with acute myocardial infarction 1999. Updated guideline [cited 2000 Jul 23]. Available from: URL: http://www.acc.org/clinical/guidelines/nov96/1999/dirindex.htm.

Ryan

Anderson

Antman

Braniff

Brooks

Califf

ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328–428.

Ryan

Antman

Brooks

Califf

Hillis

Hiratzka

1999 Updated: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100: 1016–30.

Ryan

Antman

Brooks

Califf

Hillis

Hiratzka

Cairns

Kennedy

Fuster

. Coronary thrombolysis. Chest 1998;114:6345–78.

The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989;320:618–27.

Mehta

Eikelboom

Yusuf

. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis. Lancet 2000;356:449–54.

Zabel

Granger

Becker

Bovill

Hirsh

Aylward

Use of bedside activated partial thromboplastin time monitor to adjust UFH dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Am Heart J 1998;136:868–76.

10.

A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction: The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy investigators. N Engl J Med 1997;336:1621–8. [erratum appears in N Engl J Med 1997;337:287].

11.

The COBALT Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction: The Continuous Infusion versus Double-Bolus Administration of Al-teplase (COBALT) investigators. N Engl J Med 1997;337:1124–30.

12.

A comparison of reteplase with alteplase for acute myocardial infarction: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators. N Engl J Med 1997;337:1118–23.

13.

Mahaffey

Lee

White

Gore

Weaver

Granger

Intracranial hemmorhage on the increase and beyond predicted levels: Serial results from two large thrombolysis trials (abstract). Circulation 1999;100(suppl I):I–182.

14.

The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716–22.

15.

Ferguson

. Highlights of the 48th Scientific Sessions of the American College of Cardiology. Circulation 1999;100:570–5.

16.

Seyedroudbari

Kessler

Mooss

Wurdeman

Bala

Hilleman

. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA. J Thromb Thrombolysis 2000;9:303–8.

17.

Barron

H V

Bowlby

Breen

Rogers

Canto

Zhang

Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2. Circulation 1998;97:1150–6.

18.

Simes

Topol

Holmes

Jr. White

Rutsch

Vahanian

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct related reperfusion. Circulation 1995;91:1923–8.

19.

The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–22.

20.

Kennedy

Stadius

. Combined thrombolytic and platelet glycoprotein IIb/IIIa inhibitor therapy for acute myocardial infarction. Circulation 1999;99:2714–6.

21.

Califf

. Glycoprotein IIb/IIIa blockade and thrombolytics: Early lessons from the SPEED and GUSTO IV trials. Am Heart J 1999;138 (Suppl):S12–5.

22.

Ohman

Califf

Topol

Candela

Abbotsmith

Ellis

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction: TAMI Study Group. Circulation 1990;82: 781–91.

23.

Cannon

. Overcoming thrombolytic resistance. J Am Coll Cardiol 1999;34:1395–402.

24.

Coller

. Platelets and thrombolytic therapy. N Engl J Med 1990;322: 33–42.

25.

Vaughan

Van Houtte

Declerck

Collen

. Streptokinase-induced platelet aggregation: Prevalence and mechanism. Circulation 1991;84:84–91.

26.

Cannon

. Combination therapy for acute myocardial infarction: Glycoprotein IIb/IIIa inhibitors plus thrombolysis. Clin Cardiol 1999;22(suppl IV):IV37–43.

27.

Gold

Coller

Yasuda

Saito

Fallon

Guerrero

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988;77:670–7.

28.

Kleiman

Ohman

Califf

George

Kereiakes

Aguirre

F V

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381–9.

29.

Ohman

Kleiman

Gacioch

Worley

Navetta

Talley

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997;95:846–54.

30.

Ronner

van Kesteren

HAM

Zijnen

Tebbe

Molhoek

Cuffie

Combined therapy with streptokinase and integrilin (abstract). J Am Coll Cardiol 1998;31:(suppl A):191A.

31.

The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998;32:2003–10.

32.

Antman

Giugliano

Gibson

McCabe

Coussement

Kleiman

Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation 1999;99:2720–32.

33.

Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2788–94.

34.

Meyer

Merx

Schmitz

Erbel

Kiesslich

Dorr

Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation 1982;66:905–13.

35.

O'Keefe

Rutherford

McConahay

Ligon

Johnson

Giorgi

Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989;64:1221–30.

36.

O'Keefe

Rutherford

McConahay

Johnson

Giorgi

Shimshak

Myocardial salvage with direct coronary angioplasty for acute infarction. Am Heart J 1992;123:1–6.

37.

Stone

Rutherford

McConahay

Johnson

Giorgi

Ligon

Direct coronary angioplasty in acute myocardial infarction: Outcome in patients with single vessel disease. J Am Coll Cardiol 1990;15:534–43.

38.

Kander

O'Neill

Topol

Gallison

Mileski

Ellis

. Long-term follow-up of patients treated with coronary angioplasty for acute myocardial infarction. Am Heart J 1989;118:228–33.

39.

Zijlstra

de Boer

Hoorntje

Reiffers

Reiber

Suryapranata

. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328: 680–4.

40.

Grines

Browne

Marco

Rothbaum

Stone

O'Keefe

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673–9.

41.

Michels

Yusuf

. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized trials. Circulation 1995;91:476–85.

42.

Weaver

Simes

Betriu

Grines

Zijlstra

Garcia

Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997;278:2093–8. [erratum appears in JAMA 1998;279:1876].

43.

Tiefenbrunn

Chandra

French

Gore

Rogers

. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998;31:1240–5.

44.

Hochman

Sleeper

Webb

Sanborn

White

Talley

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999;341:625–34.

45.

Ryan

. Early revascularization in cardiogenic shock — A positive view of a negative trial. N Engl J Med 1999;341:687–8.

46.

Hochman

Sleeper

Webb

Menon

Menegus

Thompson

Early revascularization for cardiogenic shock on 1 year mortality: The SHOCK trial (abstract). Circulation 1999;100(suppl I):I–369.

47.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–60.

48.

Cairns

Theroux

Lewis

Jr. Ezekowitz

Meade

Sutton

. Antithrombotic agents in coronary artery disease. Chest 1998;114 (Suppl):611S–33S.

49.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.

50.

Sharis

Cannon

C P

Loscalzo

. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394–405.

51.

Quinn

Fitzgerald

. Ticlopidine and clopidogrel. Circulation 1999;100:1667–72.

52.

Savcic

Hauert

Bachmann

Wyld

Geudelin

Cariou

. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(suppl 2):15–9.

53.

CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39.

54.

Balsano

Rizzon

Violi

Scrutinio

Cimminiello

Aguglia

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990;82:17–26.

55.

Bertrand

Rupprecht

H-J

Urban

Gershlick

. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102:624–9.

56.

Bennett

Connors

Carwile

Moake

Bell

Tarantolo

Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773–7.

57.

Mauro

Borovicka

Kline

. Introduction to coronary artery stents and their pharmacotherapeutic management. Ann Pharmacother 1997;31:1490–8.

58.

Berger

Bell

Rihal

Ting

Barsness

Garratt

Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34:1891–4.

59.

Moussa

Oetgen

Roubin

Colombo

Wang

Iye

Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364–6.

60.

Mishkel

Aguirre

Ligon

Rocha-Singh

Lucore

. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999;34:1884–90.

61.

Muller

Buttner

Petersen

Roskamm

. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590–3.

62.

Package insert. Ticlid (ticlopidine hydrochloride). Nutley, NJ: Roche Laboratories, June 2000.

63.

Granger

Hirsh

Califf

Col

White

Betriu

Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO -I trial. Circulation 1996;93:870–8.

64.

Becker

Cannon

George

Loscalso

. Toward establishing anticoagulation guidelines for intravenous heparin administration among patients with myocardial infarction given tissue plasminogen activator (abstract). J Am Coll Cardiol 1995;25:309.

65.

Brener

Vrobel

Lopez

L'Allier

Strony

Van der Wieken

INTRO AMI: Marked enhancement of arterial patency with eptifibatide and low-dose TPA in acute myocardial infarction (abstract). Circulation 1999;199(suppl I):I–649.

66.

Raschke

Reilly

Guidry

Fontana

Srinivas

. The weight-based heparin dosing nomogram compared with a “standard care” nomogram: A randomized controlled trial. Ann Intern Med 1993;119:874–81.

67.

Cannon

Gibson

McCabe

Adgey

AAJ

Schweiger

Sequeira

TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Circulation 1998;98:2805–14.

68.

Antman

McCabe

Gurfinkel

Turpie

Bernink

Salein

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100: 1593–601.

69.

Liem

Zijlstra

Ottervanger

J P

Hoorntje

JCA

Suryapranata

de Boer

M-J

High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000;35:600–4.

70.

Kaluski

Krakover

Cotter

Hendler

Zyssman

Milovanov

Minimal heparinization in coronary angioplasty — How much heparin is really warranted?

Am J Cardiol 2000;85:953–6.

71.

Schomig

Kastrati

Dirschinger

Mehilli

Schricke

Pache

Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000;343:385–91.

72.

The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87–92.

73.

Fitzgerald

Singh

. Effects of β -blockers on cardiovascular morbidity and mortality in coronary artery disease. In: Singh

Dzau

Vanhoutte

Woosley

, eds. Cardiovascular pharmacology and therapeutics. New York: Churchill Livingstone, 1994:321.

74.

Ceremuzynski

. Hormonal and metabolic reactions evoked by acute myocardial infarction. Circ Res 1981;48:767–72.

75.

Opie

. Glucose and the metabolism of ischaemic myocardium. Lancet 1995;345:1520–1.

76.

Black

Stevenson

. Pharmacology of a new beta receptor blocking compound (Nethalide). Lancet 1:231.

77.

Fitzgerald

. The role of beta adrenergic blockade in acute myocardial ischemia. In: Olive

Julian

Donald

K W

, eds. Effect of acute ischaemia on myocardial function. Edinburgh: Churchill Livingstone, 1972:295.

78.

Opie

Thomas

. Propranolol and experimental myocardial infarction: Substrate effects. Postgrad Med J 1976;52(suppl 4):124–6.

79.

Fitzgerald

. The effects of beta adrenoceptor blocking drugs on early arrhythmias in experimental and clinical myocardial ischaemia. In: Parrat

, ed. Early arrhythmias resulting from myocardial ischaemia: Mechanism and prevention by drugs. London: Macmillan, 1982:518.

80.

ISIS-I Study Group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-I. Lancet 1986:2:57–66.

81.

Lau

Antman

Jimenez-Silva

Kupelnick

Mosteller

Chalmers

. Cumulative meta-analysis of therapeutic trials in myocardial infarction. N Engl J Med 1992;327:248–54.

82.

Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial I: Congestive heart failure. Lancet 1999;353:2000–7.

83.

Krum

. β-Blockers in heart failure: The new wave of clinical trials. Drugs 1999;58:203–10.

84.

Carvedilol Prospective Randomized Cumulative Survival Trial. [cited 2000 Aug 11]. Available from: URL: http://www.cardiosource.com/site.mash?left=&m1=3&m2=3&right=/trials/trialsearch.

85.

Wilhelmsson

Vedin

Wilhelmsen

. Cost benefit aspects of post-myocardial infarction intervention. Symposium on acute and long term management of myocardial ischaemia. Acta Med Scand 1981;651:317–25.

86.

Pratt

Roberts

. Chronic beta-blocker therapy in patients with myocardial infarction. Am J Cardiol 1983;52:661–6.

87.

Olsson

Bowden

Johansson

Sjogren

Rehqvist

. Prognosis after withdrawal of chronic post-infarction metoprolol treatment: A 2–7 year follow up. Eur Heart J 1988;9:365–72.

88.

Phillips

Yim

Brown

Bittar

Hoon

Celestin

Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J 1996;131:872–8.

89.

Braunwald

. Unstable angina. An etiologic approach to management. Circulation 1998;98:2219–22.

90.

Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429–35.

91.

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498–505.

92.

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q—wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488–97.

93.

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436–43.

94.

Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422–8.

95.

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina and acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997;96:1445–52.

96.

Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956–61.

97.

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689–96.

98.

Low-molecular weight heparin during instability in coronary artery disease. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347:561–8.

99.

Klein

Buchwald

Hillis

Monrad

Sanz

Turpie

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61–8.

100.

Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:701–7.

101.

Cohen

Demers

Gurfinkel

Turpie

Frommell

Goodman

A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447–52.

102.

Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708–15.

103.

Goodman

Cohen

Bigonzi

Furfinkel

Radley

Le Iouer

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q—Wave Coronary Events. J Am Coll Cardiol 2000;36:693–8.

104.

Antman

Cohen

Radley

McCabe

Rush

Premmereur

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q—wave myocardial infarction. TIMI 11B—ESSENCE meta-analysis. Circulation 1999;100:1602–8.

105.

A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335:775–82.

106.

Antman

. Hirudin in acute myocardial infarction. Thrombosis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911–21.

107.

Comparison of the effects of 2 doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Circulation 1997;96:769–77.

108.

Effects of recombinant hirudin (lepirudin) compared to heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Lancet 1999;353:429–38.

109.

Serruys

Herrman

Simon

Rutsch

Bode

Laarman

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995;333:757–63.

110.

Smith

Arnesen

Holme

. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147–52.

111.

Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389–96.

112.

Hirsh

Dalen

Anderson

Poller

Bussey

Ansell

Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114 (5 suppl):445S–69S.

113.

Ezekowitz

Russell

Jr.

CHAMP (Combination Hemotherapy and Mortality Prevention): Warfarin plus ASA vs. ASA alone after MI. In: Weinberg

, ed. ACCEL audiotapes. Bethesda, MD: American College of Cardiology, January 2000;52: Tape a: Side 2.

114.

The Veterans Administration Cooperative Study Program Trial. Combination, hemotherapy and mortality prevention (CHAMP): Rates of major hemorrhage (abstract). J Am Coll Cardiol 2000;35(suppl A):373A.

115.

Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

116.

Sacks

Pfeffer

Moye

Rouleau

Rutherford

Cole

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9.

117.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57.

118.

Knopp

. Drug treatment of lipid disorders. N Engl J Med 1999;341: 498–511.

119.

Canner

Berge

Wenger

Stamler

Friedman

Prineas

Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–55.

120.

Rubins

Robins

Collins

Fye

Anderson

Elam

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–8.

121.

Jeng

Sheu

Lee

Huang

Shieh

. Gemfibrozil treatment of hypertriglyceridemia: Improvement in fibrinolysis without change of insulin resistance. Am Heart J 1997;134:565–71.

122.

Yuan

Tsai

M Y

Hunninghake

. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1–11.

123.

Frick

Heinonen

Huttunen

Koskinen

Mannttari

Manninen

. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med 1993;25:41–5.

124.

The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21–7.

125.

Gotto

Jr.

Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998;82(Suppl):22Q–5Q.

126.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015–23.

127.

Steinberg

Parthasarathy

Carew

Khoo

Witztum

. Beyond cholesterol modifications of low-density lipoprotein cholesterol that increase its atherogenicity. N Engl J Med 1989;320:9115–24.

128.

Mitchinson

. The new face of atherosclerosis. Br J Clin Pract 1994;48:149–51.

129.

Stampfer

Hennekens

Manson

Colditz

Rosner

Willett

. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 1993;328:1444–9.

130.

Rimm

Stampfer

Ascherio

Giovannucci

Colditz

Willett

. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450–6.

131.

Blot

Taylor

Guo

Dawsey

Wang

G Y

Nutrition intervention trial in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483–92.

132.

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330: 1029–35.

133.

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1999;354:447–55.

134.

Yusuf

Dagenais

Pogue

Bosch

Sleight

. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154–60.

135.

Stephens

Parsons

Schofield

Kelly

Cheeseman

Mitchinson

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.

136.

Tribble

, for the Nutrition Committee of the AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and β -carotene. Circulation 1999;99:591–5.

137.

Hulley

Grady

Bush

Furberg

Herrington

Riggs

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280: 605–13.

138.

Rodstrom

Bengtsson

Lissner

Bjorkelund

. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: Prospective cohort study in Gothenburg, Sweden. BMJ 1999;319:890–3.

139.

The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208.

140.

Mendelsohn

Karas

. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801–12.

141.

Ridker

Hennekens

Rifai

Buring

Manson

. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713–6.

142.

Cushman

Legault

Barrett-Connor

Stefanik

Kessler

Judd

Effect of postmenopausal hormones on inflammation-sensitive proteins. The Post menopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999;100:717–22.

143.

Post

Goldschmidt-Clermont

Wilhide

Heldman

Sussman

Ouyang

Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985–91.

144.

Herrington

Reboussin

Brosnihan

Sharp

Shumaker

Snyder

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–9.

145.

Jeffrey

. Heartwire News. DSMB prompts NHLBI to send letter to WHI participants [cited 2000 April 4]. Available from: URL: http://www.theheart.org/index.cfm.

146.

US Department of Health and Human Services. The health consequences of smoking: cardiovascular disease. A report of the Surgeon General. Rockville, MD: Department of Health and Human Services, 1983: DHSS(PHS) no. 84–50204.

147.

Maouad

Fernandez

Barrillon

Gerbaux

Gay

. Diffuse or segmental narrowing (spasm) of the coronary arteries during smoking demonstrated on angiography. Am J Cardiol 1984;53:354–5.

148.

Solymoss

Nadeau

Millette

Campeau

. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988;78(suppl 1):140–3.

149.

Walle

Byington

Furberg

McIntyre

Vokonas

. Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 1985;38:509–18.

150.

Aberg

Berstrand

Johansson

Ulvenstam

Vedin

Wedel

Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J 1983;49:416–22.

151.

Baile

Bigelow

Gottlieb

Stitzer

Sacktor

. Rapid resumption of cigarette smoking following myocardial infarction: Inverse relation to MI severity. Addict Behav 1982;7:373–80.

152.

Daly

Mulcahy

Graham

Hickey

. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J (Clin Res) 1983;287:324–6.

153.

Schwartz

. Methods of smoking cessation. Med Clin North Am 1992;76:451–76.

154.

Taylor

Houston-Miller

Killen

DeBusk

. Smoking after acute myocardial infarction: Effect of a nurse-managed intervention. Ann Intern Med 1990;113:118–23.

155.

Joseph

Norman

Ferry

Prochazka

Westman

Steele

The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792–8.

156.

Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease: Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994;154:989–95.

157.

Murray

Bailey

Daniels

Bnornson

Kurnow

Connett

Safety of nicotine polacrilex gum used by 3094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996;109:438–45.

158.

Hughes

Goldstein

Hurt

Shiffman

. Recent advances in pharmacotherapy of smoking cessation. JAMA 1999;281:72–6.

159.

Hurt

Sachs

Glover

Offord

Johnston

Dale

A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195–202.

160.

Kiev

Masco

Wenger

Johnston

Batey

Holloman

The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry 1994;6:107–15.

161.

Roose

Dalack

Glassman

Woodring

Walsh

Glardina

Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512–6.

162.

Scholl

Benacerraf

Ducimetiere

Chaba

Brau

Chapelle

Comparison of risk factors in vasospastic angina without significant fixed coronary narrowing to significant fixed coronary narrowing and no vasospastic angina. Am J Cardiol 1986;57:199–202.